{"id":153453,"date":"2025-06-03T00:35:17","date_gmt":"2025-06-03T00:35:17","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/153453\/"},"modified":"2025-06-03T00:35:17","modified_gmt":"2025-06-03T00:35:17","slug":"biontech-gains-20-on-11-1-billion-bristol-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/153453\/","title":{"rendered":"BioNTech Gains 20% On $11.1 Billion Bristol Deal"},"content":{"rendered":"\n<p class=\"yf-1090901\">BioNTech (<a class=\"link \" href=\"https:\/\/finance.yahoo.com\/quote\/BNTX\" data-ylk=\"slk:NASDAQ:BNTX;elm:context_link;itc:0;sec:content-canvas\" target=\"_blank\" rel=\"noopener\">NASDAQ:BNTX<\/a>) surged 20% after Bristol Myers Squibb (<a class=\"link \" href=\"https:\/\/finance.yahoo.com\/quote\/BMY\" data-ylk=\"slk:NYSE:BMY;elm:context_link;itc:0;sec:content-canvas\" target=\"_blank\" rel=\"noopener\">NYSE:BMY<\/a>) <a href=\"https:\/\/seekingalpha.com\/news\/4454424-biontech-license-bispecific-antibody-bristol-in-up-to-11_1b-deal\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:agreed to license its bispecific antibody;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">agreed to license its bispecific antibody<\/a> BNT327targeting PD-L1 and VEGF-Afor solid tumors in a deal worth up to $11.1 billion.<\/p>\n<p class=\"yf-1090901\">Under the agreement, BMY will pay a $1.5 billion upfront fee and $2 billion in guaranteed payments through 2028, with BioNTech eligible for up to $7.6 billion in milestones. Both companies will fund development and manufacturing costs equally and split global profits or losses. BNT327 is currently in a Phase 3 trial as a first-line treatment for extensive-stage small-cell and non-small-cell lung cancers, and a Phase 3 study in triple-negative breast cancer will launch by year-end. BMY and BNTX retain rights to pursue additional indications and combination regimens.<\/p>\n<p class=\"yf-1090901\">Street analysts applauded the collaboration. BMO Capital Markets&#8217; Evan David Seigerman noted that Bristol gains a next-generation molecule to potentially replace Opdivo, while BioNTech taps Bristol&#8217;s global distribution and oncology development expertise. Raymond James&#8217; Sean McCutcheon added that the move shores up Bristol&#8217;s mid- to long-term growth pipeline ahead of an anticipated Opdivo revenue gap post-2028.<\/p>\n<p class=\"yf-1090901\">Investors should care because this partnership accelerates BNT327&#8217;s path to market with a Tier 1 oncology partner, de-risks late-stage development, and provides BioNTech with substantial non-dilutive capitalwhile Bristol secures a promising immunotherapy to bolster its portfolio.<\/p>\n<p class=\"yf-1090901\">With the first $1.5 billion payment already recognized, markets will focus on upcoming BNT327 Phase 3 readouts and any future milestone announcements that unlock the remaining $7.6 billion.<\/p>\n<p class=\"yf-1090901\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/2902478\/biontech-gains-20-on-111-billion-bristol-deal?r=caf6fe0e0db70d936033da5461e60141\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">GuruFocus<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"BioNTech (NASDAQ:BNTX) surged 20% after Bristol Myers Squibb (NYSE:BMY) agreed to license its bispecific antibody BNT327targeting PD-L1 and&hellip;\n","protected":false},"author":2,"featured_media":153454,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8818],"tags":[65338,381,23890,748,393,4884,65337,16,15],"class_list":{"0":"post-153453","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-bristol","8":"tag-biontech","9":"tag-bristol","10":"tag-bristol-myers-squibb","11":"tag-britain","12":"tag-england","13":"tag-great-britain","14":"tag-raymond-james","15":"tag-uk","16":"tag-united-kingdom"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/153453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=153453"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/153453\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/153454"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=153453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=153453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=153453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}